Nano-X Imaging experienced a 15% increase in value today, fueling speculation about its success.
In a significant development, Nano-X Imaging, a pioneering medical technology specialist, has announced its fourth-quarter results, revealing a revenue of $1.3 million - a substantial increase from the zero revenue reported in the same quarter the previous year. However, the company's non-GAAP net loss for the quarter was more than $39 million ($0.81 per share), marking a significant increase from the net loss of $18.9 million in the same quarter of 2020.
The stock price of Nano-X Imaging saw an increase of over 15% on Thursday following the publication of the fourth-quarter results, despite the larger-than-anticipated net loss. Analysts had collectively anticipated around $750,000 in revenue for the quarter, but expected a much narrower adjusted, per-share net loss of $0.33.
CEO Erez Meltzer revealed that the company has filed new paperwork for the latest version of Nanox.ARC, its leading product. The single-source Nanox.ARC has already received FDA 510(k) clearance and is commercially available, while the Nanox.ARC X, a multi-source digital tomosynthesis system, received FDA 510(k) clearance on April 17, 2025. However, the FDA has placed a hold on the regulatory submission for the Nanox.ARC multisource X-ray system, requesting additional information to address certain deficiencies identified in the filing.
The Nanox.ARC X system produces advanced tomographic images with better clarity and reduced structural overlap compared to traditional 2D X-rays. Its clearance allows its use for imaging musculoskeletal system, lungs, abdomen, and sinuses. It features a compact design and supports remote software upgrades.
Beyond FDA clearance, Nanox.ARC also secured the CE Mark in early 2025, enabling market access in Europe, and is being integrated into clinical and educational programs like at Keiser University to promote adoption and training.
Meltzer also mentioned that the company is in continuous communication with the FDA regarding the device. The ongoing FDA hold on the related multisource X-ray submission is pending additional information from Nanox.
It is important to note that Nanox has started earning money for the first time, as revealed in Thursday's news. The company's cheaper imaging technology, compared to the commonly used expensive solutions in healthcare providers, is expected to contribute to its growing revenue in the future.
The Q4 results and regulatory updates have reignited investor interest in Nano-X Imaging, demonstrating the company's commitment to advancing regulatory and clinical milestones to expand the system's applications and market reach.
- Despite the larger-than-anticipated net loss, the stock price of Nano-X Imaging increased by over 15% following the publication of the fourth-quarter results, suggestive of investor interest.
- Nanox.ARC, the leading product of Nano-X Imaging, has already received FDA 510(k) clearance and is commercially available, while its multi-source counterpart, Nanox.ARC X, received clearance on April 17, 2025.
- The Nanox.ARC X system, with its advanced tomographic images, is being integrated into clinical and educational programs like at Keiser University to promote adoption and training, hinting at its growing popularity in the health-and-wellness sector.
- The company's cheaper imaging technology, compared to the commonly used expensive solutions in healthcare providers, is expected to contribute to its growing revenue in the future, indicating a potential impact on the overall finance and investing landscape in science and technology.
